Omalizumab (Xolair) prior authorization for allergic asthma and chronic urticaria
Customize your policy alerts
Sign up for all AmeriHealth policy alerts
Know when AmeriHealth releases new policies or updates existing guidance.
Monitor payer policy activity
Form and criteria governing prior authorization and delivery of omalizumab (Xolair) for patients with allergic asthma or chronic spontaneous urticaria; intended for prescribing physicians submitting requests to AmeriHealth.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.